Publication:

Glycomic regulation of human B cells

Loading...
Thumbnail Image

Date

2018-09-16

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Abstract

All leukocytes are coated with a dense layer of carbohydrates called the glycocalyx. Initially believed to serve largely biophysical roles, the glycocalyx is increasingly recognized as a gatekeeper of leukocyte interactions with the cellular microenvironment, in part by mediating specific contacts with carbohydrate-binding proteins (lectins). Far from inert bystanders, the carbohydrate moieties (glycans) decorating leukocyte glycoproteins are highly dynamic and undergo significant restructuring in different immunological contexts. On T cells, which confer cell-mediated immunity, activation and differentiation are known to induce global alterations in the T cell glycan repertoire (glycome) that regulate T cell survival and homing to inflamed tissues. Yet, for B cells, which confer humoral immunity, similar alterations to the glycome have not been extensively reported. Here, we tested the hypothesis that glycomic changes associated with B cell differentiation are critical for normal B cell function. This hypothesis was tested in two related studies. In the first study, we profiled the repertoire of asparagine (N)-linked glycans expressed by B cells at multiple stages of differentiation, including naïve, germinal center (GC), and memory B cell stages. Results from this study revealed that while all B cells expressed N-glycans replete with lactosamine chains, these lactosamine moieties were modified with I-branches in GC B cells due to upregulation of the glycosyltransferase GCNT2. Functional studies revealed that I-branches served as a selective regulator of binding of a family of immunoregulatory lectins known as galectins. In the second study, the function of one of these galectins, galectin-9, was investigated in B cells. These studies revealed that galectin-9 was highly expressed by naïve B cells and bound the glycoprotein CD45. Mechanistically, galectin-9 promoted inhibitory signaling via the Lyn-CD22-SHP-1 pathway and ultimately attenuated B cell receptor-mediated calcium signaling and activation. Perturbation of B cell-intrinsic galectin-9 revealed that galectin-9 could serve as an autologous regulator of B cell receptor signaling. In all, our study highlights a novel glycomic mechanism regulating B cell activation, and opens new avenues of investigation into the roles of galectin-9 in B cell peripheral tolerance and autoimmune disease.

Description

Other Available Sources

Research Data

Keywords

Biology, Cell, Biology, Molecular, Biology, General

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories